Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study.

Fredheim OM, Borchgrevink PC, Hegrenaes L, Kaasa S, Dale O, Klepstad P.

J Pain Symptom Manage. 2006 Aug;32(2):180-5.

PMID:
16877186
2.

Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.

Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN.

J Pharmacol Exp Ther. 2006 Mar;316(3):1098-106.

3.

Effects of methadone on QT-interval dispersion.

Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH.

Pharmacotherapy. 2005 Nov;25(11):1523-9.

PMID:
16232014
4.

Methadone-induced Torsade de pointes tachycardias.

Sticherling C, Schaer BA, Ammann P, Maeder M, Osswald S.

Swiss Med Wkly. 2005 May 14;135(19-20):282-5. Review.

PMID:
15986265
5.

Measurement of QTc in patients receiving chronic methadone therapy.

Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Sheu RG, Portenoy RK.

J Pain Symptom Manage. 2005 Apr;29(4):385-91.

PMID:
15857742
6.

Impact of methadone treatment on cardiac repolarization and conduction in opioid users.

Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN.

Am J Cardiol. 2005 Apr 1;95(7):915-8.

PMID:
15781034
7.

QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone.

Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, Segura F.

Am J Cardiol. 2003 Oct 15;92(8):995-7.

PMID:
14556883
8.

QTc interval prolongation associated with intravenous methadone.

Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL.

Pain. 2003 Oct;105(3):499-506.

PMID:
14527710
9.

High dose methadone and ventricular arrhythmias: a report of three cases.

Walker PW, Klein D, Kasza L.

Pain. 2003 Jun;103(3):321-4.

PMID:
12791438
10.

What clinicians should know about the QT interval.

Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM.

JAMA. 2003 Apr 23-30;289(16):2120-7. Review. Erratum in: JAMA. 2003 Sep 10;290(10):1318.

PMID:
12709470
11.

Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.

Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN.

J Pharmacol Exp Ther. 2002 Nov;303(2):688-94.

12.

Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes.

Bolan EA, Tallarida RJ, Pasternak GW.

J Pharmacol Exp Ther. 2002 Nov;303(2):557-62.

13.

Torsade de pointes associated with very-high-dose methadone.

Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS.

Ann Intern Med. 2002 Sep 17;137(6):501-4.

PMID:
12230351
14.

Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.

Santiago-Palma J, Khojainova N, Kornick C, Fischberg DJ, Primavera LH, Payne R, Manfredi P.

Cancer. 2001 Oct 1;92(7):1919-25.

PMID:
11745266
15.

Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy.

Manfredi PL, Gonzales GR, Cheville AL, Kornick C, Payne R.

J Pain Symptom Manage. 2001 Feb;21(2):169-74.

PMID:
11226767
17.

d-Methadone is antinociceptive in the rat formalin test.

Shimoyama N, Shimoyama M, Elliott KJ, Inturrisi CE.

J Pharmacol Exp Ther. 1997 Nov;283(2):648-52.

18.

Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations.

Manfredi PL, Borsook D, Chandler SW, Payne R.

Pain. 1997 Mar;70(1):99-101.

PMID:
9106815
19.
Items per page

Supplemental Content

Support Center